Teva Pharmaceutical Industries Ltd (TEVA): who owns it and who trades it
As of Nov 16, 2026, TEVA insiders reported 64 open-market sales worth $125M and no purchases in the last 12 months, with 8% of the sale value made under pre-set 10b5-1 plans. The largest seller was Richard D Francis (CEO), with $41.8M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling TEVA Pharmaceutical Industries
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TEVA
673 funds and institutions reported TEVA shares worth $26.1B at the end of Q2 2026, about 67% of the company. The largest holder is BlackRock, Inc. with 5.5%.
Funds and institutions (13F) 67%Everyone else 33%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 63.89M | 5.48% | $2.2B | -2% |
| Harel Insurance Investments & Financial Services Ltd. | 48.14M | 4.13% | $1.6B | +5% |
| California State Teachers Retirement System | 43.27M | 3.71% | $1.3B | +3376% |
| Phoenix Financial Ltd. | 42.93M | 3.68% | $1.5B | +0% |
| Wcm Investment Management, LLC | 41.32M | 3.55% | $1.4B | +1% |
| Clal Insurance Enterprises Holdings Ltd | 40.60M | 3.48% | $1.4B | +6% |
| Menora Mivtachim Holdings Ltd. | 39.85M | 3.42% | $1.4B | +1% |
| Migdal Insurance & Financial Holdings Ltd. | 38.92M | 3.34% | $1.3B | +3% |
| Norges Bank | 32.30M | 2.77% | $1.1B | – |
| FMR LLC (Fidelity) | 30.26M | 2.60% | $1B | -9% |
| Lingotto Investment Management LLP | 20.21M | 1.73% | $685M | -27% |
| State Street Corp | 18.94M | 1.63% | $642M | +6% |
| Rubric Capital Management LP | 15.57M | 1.34% | $528M | +2% |
| Capital World Investors | 12.54M | 1.08% | $425M | +42% |
| Altshuler Shaham Ltd | 12.47M | 1.07% | $412M | +9% |
| Geode Capital Management, LLC | 11.61M | 1.00% | $391M | +10% |
| Meitav Investment House Ltd | 9.95M | 0.85% | $337M | – |
| Northern Trust Corp | 7.96M | 0.68% | $270M | +4% |
| Wellington Management Group LLP | 7.67M | 0.66% | $260M | +6% |
| JPMorgan Chase & Co | 6.98M | 0.60% | $233M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TEVA insiders reported $0 of open-market purchases and $125M of sales. 8% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Mark Sabag | See "Remarks" | Sale | 44,710 | $44.14 | $2M | Form 4 |
| Nov 11, 2026 | Richard Daniell | Vice president | Sale | 20,003 | $42.80 | $856K | Form 4 |
| Nov 10, 2026 | Richard D Francis | CEO | Sale plan | 250,000 | $42.24 | $10.6M | Form 4 |
| Nov 9, 2026 | Richard Daniell | Vice president | Sale | 25,000 | $42.91 | $1.1M | Form 4 |
| Nov 9, 2026 | Amir Weiss | Chief Accounting Officer | Sale | 662 | $43.15 | $28.6K | Form 4 |
| Nov 9, 2026 | Amir Weiss | Chief Accounting Officer | Sale | 7,093 | $43.03 | $305K | Form 4 |
| Nov 9, 2026 | Amir Weiss | Chief Accounting Officer | Sale | 9,534 | $43.03 | $410K | Form 4 |
| Nov 5, 2026 | Mark Sabag | See "Remarks" | Sale | 46,000 | $41.93 | $1.9M | Form 4 |
| Nov 4, 2026 | Dov Bergwerk | Interim Cheif Legal Offi | Sale | 17,505 | $41.72 | $730K | Form 4 |
| Nov 4, 2026 | Dov Bergwerk | Interim Cheif Legal Offi | Sale | 8,755 | $41.72 | $365K | Form 4 |
| Sep 18, 2026 | Brian Savage | Interim Chief Legal Offi | Sale | 314 | $38.70 | $12.2K | Form 4 |
| Sep 18, 2026 | Brian Savage | Interim Chief Legal Offi | Sale | 2,525 | $39.15 | $98.9K | Form 4 |
| Sep 18, 2026 | Brian Savage | Interim Chief Legal Offi | Sale | 4,503 | $38.69 | $174K | Form 4 |
| Sep 18, 2026 | Roberto Mignone | Director | Sale | 367,600 | $39.06 | $14.4M | Form 4 |
| Aug 21, 2026 | Amir Weiss | Chief Accounting Officer | Sale | 2,500 | $37.63 | $94.1K | Form 4 |
| Aug 21, 2026 | Amir Weiss | Chief Accounting Officer | Sale | 6,945 | $37.61 | $261K | Form 4 |
| Aug 21, 2026 | Ronit Satchi-Fainaro | Director | Sale | 415 | $37.25 | $15.5K | Form 4 |
| Aug 17, 2026 | Evan Lippman | Vice president | Sale | 18,600 | $36.57 | $680K | Form 4 |
| Aug 5, 2026 | Tal Zvi Zaks | Director | Sale | 17 | $34.87 | $593 | Form 4 |
| Aug 3, 2026 | Placid Jover | See "Remarks" | Sale | 12,827 | $34.88 | $447K | Form 4 |
| Aug 3, 2026 | Eric A Hughes | See "Remarks" | Sale | 25,578 | $34.88 | $892K | Form 4 |
| Jun 18, 2026 | Matthew Shields | Vice president | Sale | 9,989 | $32.19 | $322K | Form 4 |
| Jun 11, 2026 | Eliyahu Sharon Kalif | CFO | Sale | 106,563 | $34.10 | $3.6M | Form 4 |
| Jun 5, 2026 | Richard D Francis | CEO | Sale | 6,153 | $34.35 | $211K | Form 4 |
| Jun 3, 2026 | Matthew Shields | Vice president | Sale | 16,195 | $32.87 | $532K | Form 4 |
| May 14, 2026 | Evan Lippman | Vice president | Sale | 5,746 | $35.58 | $204K | Form 4 |
| May 14, 2026 | Evan Lippman | Vice president | Sale | 35,912 | $35.58 | $1.3M | Form 4 |
| May 14, 2026 | Eliyahu Sharon Kalif | CFO | Sale | 153,251 | $35.61 | $5.5M | Form 4 |
| May 6, 2026 | Amir Weiss | Chief Accounting Officer | Sale | 10,679 | $36.00 | $384K | Form 4 |
| May 5, 2026 | Richard Daniell | Vice president | Sale | 30,000 | $35.40 | $1.1M | Form 4 |
| May 1, 2026 | Mark Sabag | See "Remarks" | Sale | 144,180 | $34.99 | $5M | Form 4 |
| Apr 30, 2026 | Christine Fox | Vice president | Sale | 21,258 | $35.31 | $751K | Form 4 |
| Mar 17, 2026 | Mark Sabag | See "Remarks" | Sale | 62,102 | $30.14 | $1.9M | Form 4 |
| Mar 5, 2026 | Richard D Francis | CEO | Sale | 20,025 | $31.67 | $634K | Form 4 |
| Mar 5, 2026 | Christine Fox | Vice president | Sale | 7,924 | $31.67 | $251K | Form 4 |
| Mar 5, 2026 | Eric A Hughes | See "Remarks" | Sale | 9,533 | $31.67 | $302K | Form 4 |
| Mar 5, 2026 | Richard Daniell | Vice president | Sale | 17,295 | $31.67 | $548K | Form 4 |
| Mar 5, 2026 | Placid Jover | See "Remarks" | Sale | 14,150 | $31.67 | $448K | Form 4 |
| Mar 5, 2026 | Brian Savage | Interim Chief Legal Offi | Sale | 1,127 | $31.67 | $35.7K | Form 4 |
| Mar 4, 2026 | Richard D Francis | CEO | Sale | 23,393 | $32.46 | $759K | Form 4 |
| Mar 4, 2026 | Richard Daniell | Vice president | Sale | 33,512 | $32.46 | $1.1M | Form 4 |
| Mar 4, 2026 | Richard Daniell | Vice president | Sale | 37,372 | $32.95 | $1.2M | Form 4 |
| Mar 4, 2026 | Richard Daniell | Vice president | Sale | 20,461 | $32.46 | $664K | Form 4 |
| Mar 4, 2026 | Eric A Hughes | See "Remarks" | Sale | 11,277 | $32.46 | $366K | Form 4 |
| Mar 4, 2026 | Christine Fox | Vice president | Sale | 9,098 | $32.46 | $295K | Form 4 |
| Mar 4, 2026 | Brian Savage | Interim Chief Legal Offi | Sale | 1,186 | $32.46 | $38.5K | Form 4 |
| Mar 4, 2026 | Brian Savage | Interim Chief Legal Offi | Sale | 1,489 | $32.46 | $48.3K | Form 4 |
| Mar 3, 2026 | Richard Daniell | Vice president | Sale | 66,735 | $32.36 | $2.2M | Form 4 |
| Mar 3, 2026 | Richard Daniell | Vice president | Sale | 62,250 | $32.36 | $2M | Form 4 |
| Mar 3, 2026 | Brian Savage | Interim Chief Legal Offi | Sale | 1,274 | $32.36 | $41.2K | Form 4 |
| Mar 3, 2026 | Richard D Francis | CEO | Sale | 30,903 | $32.36 | $1M | Form 4 |
| Mar 3, 2026 | Richard D Francis | CEO | Sale | 412,032 | $32.36 | $13.3M | Form 4 |
| Mar 3, 2026 | Eric A Hughes | See "Remarks" | Sale | 12,077 | $32.36 | $391K | Form 4 |
| Mar 3, 2026 | Eric A Hughes | See "Remarks" | Sale | 68,685 | $32.36 | $2.2M | Form 4 |
| Feb 26, 2026 | Eliyahu Sharon Kalif | CFO | Sale | 345,810 | $33.64 | $11.6M | Form 4 |
| Feb 15, 2026 | Richard D Francis | CEO | Sale | 161,656 | $34.22 | $5.5M | Form 4 |
| Feb 15, 2026 | Richard D Francis | CEO | Sale | 286,122 | $34.22 | $9.8M | Form 4 |
| Dec 16, 2025 | Amir Weiss | Chief Accounting Officer | Sale | 12,300 | $30.20 | $371K | Form 4 |
| Dec 16, 2025 | Roberto Mignone | Director | Sale | 77,400 | $30.24 | $2.3M | Form 4 |
| Dec 9, 2025 | Richard Daniell | Vice president | Sale | 115,468 | $28.68 | $3.3M | Form 4 |
| Dec 9, 2025 | Mark Sabag | See "Remarks" | Sale | 98,168 | $28.70 | $2.8M | Form 4 |
| Dec 9, 2025 | Mark Sabag | See "Remarks" | Sale | 118,724 | $28.75 | $3.4M | Form 4 |
| Nov 26, 2025 | Roberto Mignone | Director | Sale | 50,000 | $26.03 | $1.3M | Form 4 |
| Nov 20, 2025 | Christine Fox | Vice president | Sale | 28,229 | $24.78 | $700K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Richard D Francis | President and CEO | – | $41.8M | Nov 10, 2026 |
| Eliyahu Sharon Kalif | EVP, Chief Financial Officer | – | $20.7M | Jun 11, 2026 |
| Roberto Mignone | Director | – | $18M | Sep 18, 2026 |
| Mark Sabag | See "Remarks" | – | $17M | Nov 12, 2026 |
| Richard Daniell | Exec. VP, European Commercial | – | $14M | Nov 11, 2026 |
| Eric A Hughes | See "Remarks" | – | $4.2M | Aug 3, 2026 |
| Evan Lippman | EVP, Business Development | – | $2.2M | Aug 17, 2026 |
| Christine Fox | EVP, Head of U.S. Commercial | – | $2M | Apr 30, 2026 |
| Amir Weiss | Chief Accounting Officer | – | $1.9M | Nov 9, 2026 |
| Dov Bergwerk | Interim Cheif Legal Officer | – | $1.1M | Nov 4, 2026 |
| Placid Jover | See "Remarks" | – | $896K | Aug 3, 2026 |
| Matthew Shields | EVP, Global Operations | – | $854K | Jun 18, 2026 |
| Brian Savage | Interim Chief Legal Officer | – | $449K | Sep 18, 2026 |
| Ronit Satchi-Fainaro | Director | – | $15.5K | Aug 21, 2026 |
| Tal Zvi Zaks | Director | – | $593 | Aug 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TEVA short interest
Low short interest. 2.4% of TEVA shares are sold short: about 1 share in 42. Over the last 12 reports the number of shares short went up 4%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 27.74M TEVA shares were sold short, 2.4% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 5.23M shares, buying them all back would take about 5.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 27.74M | 2.38% | -1% | 5.23M | 5.3 |
| Oct 15, 2026 | 28.07M | 2.41% | -6% | 7.16M | 3.9 |
| Sep 30, 2026 | 29.85M | 2.56% | -5% | 5.53M | 5.4 |
| Sep 15, 2026 | 31.48M | 2.70% | +11467% | 1.15M | 27.4 |
| Aug 31, 2026 | 37.61M | 3.23% | +5% | 4.88M | 7.7 |
| Aug 14, 2026 | 35.67M | 3.06% | +4% | 5.38M | 6.6 |
| Jul 31, 2026 | 34.32M | 2.95% | +5% | 5.98M | 5.7 |
| Jul 15, 2026 | 32.74M | 2.81% | +2% | 5.03M | 6.5 |
| Jun 30, 2026 | 32.03M | 2.75% | -4% | 6.28M | 5.1 |
| Jun 15, 2026 | 33.35M | 2.86% | -2% | 6.15M | 5.4 |
| May 29, 2026 | 33.87M | 2.91% | +27% | 5.65M | 6.0 |
| May 15, 2026 | 26.65M | 2.29% | -14% | 6.68M | 4.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded TEVA
Since Nov 17, 2024, 1 member of Congress reported 1 purchase and 0 sales of TEVA. The latest was a purchase by Alan Armstrong on Mar 30, 2026, reported Jul 21, 2026.
Purchases 1Sales 0
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
TEVA Pharmaceutical Industries company events
TEVA Pharmaceutical Industries filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Oct 29, 2026LeadershipAt a meeting of the Board of Directors of Teva Pharmaceutical Industries Ltd., the Board elected Dr. David J. Brailer to serve as a member of the Board, effective November 3, 2026, until Teva’s 2027 annual meeting of shareholders. Filing
- Sep 16, 2026Agreement(i) Teva Pharmaceutical Finance Netherlands II B.V., a wholly owned subsidiary of Teva Pharmaceutical Industries Limited, issued €1,000,000,000 of 4.250% Senior Notes due 2033 and €500,000,000 of 4.625% Senior Notes due 2036 (the “ 2036 Euro Notes ” and, together with the 2033 Euro Notes, the “… Filing
- Sep 14, 2026AnnouncementResults of Operations and Financial Condition. Filing
- Sep 11, 2026AnnouncementTeva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and together with Teva Finance II and Teva Finance III, the “Issuers”) and, the Company, as guarantor, entered into an underwriting… Filing
- Sep 3, 2026AnnouncementTeva Pharmaceutical Industries Limited is filing this Current Report on Form 8-K to recast historical segment information as set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 3, 2026. Filing
- Sep 3, 2026SharesChanged the rights of its shareholders. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- May 28, 2026VoteReported shareholder vote results. Filing
- Apr 29, 2026ResultsReleased financial results. Filing
- Jan 28, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 11, 2025AgreementTeva Pharmaceutical Industries Limited obtained the consent of each of the lenders party to its Revolving Facility Agreement (as defined below) to extend the stated maturity date of the commitments and loans thereunder from April 29, 2027 to April 29, 2028, and to amend certain terms of the… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
TEVA Pharmaceutical Industries financials
Famous investors that hold TEVA
7 of the 50 well-known investors we track reported holding TEVA in their latest 13F filing. The largest position is Larry Robbins's, worth $300M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Larry Robbins · Glenview Capital Management | Q3 2026 | 7.57M | $300M | 5.3% | New |
| David Einhorn · Greenlight Capital (DME) | Q3 2026 | 1.82M | $72M | 2.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 1.47M | $58M | 0.0% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 982,873 | $38.9M | 0.2% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 766,167 | $30.3M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 440,000 | $17.4M | 0.1% | New |
| Cathie Wood · ARK Investment Management | Q3 2026 | 68,295 | $2.7M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named TEVA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Phoenix Financial Ltd. | 13G/A | 4.8% |
| Nov 16, 2026 | Phoenix Financial Ltd. | 13G/A | 4.8% |
| Nov 10, 2026 | MENORA MIVTACHIM HOLDINGS LTD. | 13G/A | 5.0% |
| Nov 10, 2026 | MENORA MIVTACHIM HOLDINGS LTD. | 13G/A | 5.0% |
| Nov 2, 2026 | Harel Insurance Investments & Financial Services Ltd. | 13G/A | 6.0% |
| Nov 2, 2026 | Harel Insurance Investments & Financial Services Ltd. | 13G/A | 6.0% |
Questions about Teva Pharmaceutical Industries Ltd (TEVA) stock
Who owns the most TEVA stock?
The largest reported owner of Teva Pharmaceutical Industries Ltd (TEVA) is BlackRock, Inc., with 5.5% of the company. In total, 673 funds and institutions reported holding TEVA at the end of Q2 2026, together about 67% of the shares. See the largest owners.
Are TEVA insiders buying or selling?
In the last 12 months, TEVA insiders reported no open-market purchases and 64 sales worth $125M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in TEVA?
As of Oct 30, 2026, 27.74M TEVA shares were sold short, 2.4% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 5.23M shares, buying them all back would take about 5.3 trading days (days to cover). See the history.
Have members of Congress traded TEVA?
Yes. 1 member of Congress reported 1 purchase and 0 sales of TEVA since Nov 17, 2024. The latest was reported on Jul 21, 2026. See the trades.
Which famous investors hold TEVA?
7 of the 50 well-known investors we track reported TEVA in their latest 13F filing, including Larry Robbins, David Einhorn, Israel Englander. The largest position is worth $300M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.